103 results on '"Arbustini, Eloisa"'
Search Results
2. In vivo vulnerability grading system of plaques causing acute coronary syndromes: An intravascular imaging study
- Author
-
Prati, Francesco, Gatto, Laura, Romagnoli, Enrico, Limbruno, Ugo, Fineschi, Massimo, Marco, Valeria, Albertucci, Mario, Tamburino, Corrado, Crea, Filippo, Alfonso, Fernando, and Arbustini, Eloisa
- Published
- 2018
- Full Text
- View/download PDF
3. Common presentation of rare diseases: Aortic aneurysms & valves
- Author
-
Arbustini, Eloisa, Favalli, Valentina, Di Toro, Alessandro, Giuliani, Lorenzo, and Limongelli, Giuseppe
- Published
- 2018
- Full Text
- View/download PDF
4. Management of Adults With Anomalous Aortic Origin of the Coronary Arteries: State-of-the-Art Review.
- Author
-
Gaudino, Mario, Di Franco, Antonino, Arbustini, Eloisa, Bacha, Emile, Bates, Eric R., Cameron, Duke E., Cao, Davide, David, Tirone E., De Paulis, Ruggero, El-Hamamsy, Ismail, Farooqi, Kanwal M., Girardi, Leonard N., Gräni, Christoph, Kochav, Jonathan D., Molossi, Silvana, Puskas, John D., Rao, Sunil V., Sandner, Sigrid, Tatoulis, James, and Truong, Quynh A.
- Abstract
As a result of increasing adoption of imaging screening, the number of adult patients with a diagnosis of anomalous aortic origin of the coronary arteries (AAOCA) has grown in recent years. Existing guidelines provide a framework for management and treatment, but patients with AAOCA present with a wide range of anomalies and symptoms that make general recommendations of limited applicability. In particular, a large spectrum of interventions can be used for treatment, and there is no consensus on the optimal approach to be used. In this paper, a multidisciplinary group of clinical and interventional cardiologists and cardiac surgeons performed a systematic review and critical evaluation of the available evidence on the interventional treatment of AAOCA in adult patients. Using a structured Delphi process, the group agreed on expert recommendations that are intended to complement existing clinical practice guidelines. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. The MOGE(S) Classification for a Phenotype–Genotype Nomenclature of Cardiomyopathy: Endorsed by the World Heart Federation
- Author
-
Arbustini, Eloisa, Narula, Navneet, Dec, G. William, Reddy, K. Srinath, Greenberg, Barry, Kushwaha, Sudhir, Marwick, Thomas, Pinney, Sean, Bellazzi, Riccardo, Favalli, Valentina, Kramer, Christopher, Roberts, Robert, Zoghbi, William A., Bonow, Robert, Tavazzi, Luigi, Fuster, Valentin, and Narula, Jagat
- Published
- 2013
- Full Text
- View/download PDF
6. Acute necrotizing eosinophilic myocarditis presenting with cardiogenic shock after mRNA booster dose for COVID-19: Case report and review of literature.
- Author
-
Abete, Raffaele, Valastro, Pietro, Iacovoni, Attilio, Vittori, Claudia, Arbustini, Eloisa, Pellicioli, Federica, Schiavo, Alessandra, Grazioli, Lorenzo Stephan Cesare, Lorini, Ferdinando Luca, and Senni, Michele
- Abstract
Copyright of Journal of Cardiology Cases is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
7. From plaque biology to clinical setting
- Author
-
Arbustini, Eloisa, Morbini, Patrizia, Dal Bello, Barbara, Prati, Francesco, and Specchia, Giuseppe
- Subjects
Heart attack -- Causes of ,Atherosclerosis -- Development and progression ,Health - Published
- 1999
8. Aortic Smooth Muscle Detraining in Continuous Flow LVAD: Out of Practice.
- Author
-
Arbustini, Eloisa and Narula, Navneet
- Subjects
- *
AORTA , *SMOOTH muscle , *HEART assist devices , *HEART transplantation , *AORTIC dissection , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *AORTIC valve insufficiency - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients
- Author
-
Arbustini, Eloisa, Merlini, Giampaolo, Gavazzi, Antonello, Grasso, Maurizia, Diegoli, Marta, Fasani, Roberta, Bellotti, Vittorio, Marinone, Gabriella, Morbini, Patrizia, Dal Bello, Barbara, Campana, Carlo, and Ferrans, Victor J.
- Subjects
Amyloidosis -- Physiological aspects ,Health - Published
- 1995
10. On the Shades of Coronary Calcium and Plaque Instability.
- Author
-
Arbustini, Eloisa, Vengrenyuk, Yuliya, and Narula, Jagat
- Subjects
- *
CALCIUM , *SHEARING force , *SUDDEN death , *TORTUOSITY - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Expression of proliferating cell markers in normal and diseased human hearts
- Author
-
Arbustini, Eloisa, Diegoli, Marta, Grasso, Maurizia, Fasani, Roberta, D'Armini, Andrea, Martinelli, Luigi, Goggi, Claudio, Campana, Carlo, Gavazzi, Antonello, and Vigano, Mario
- Subjects
Heart muscle -- Physiological aspects ,Muscle cells -- Physiological aspects ,Heart diseases -- Physiological aspects ,Health - Abstract
Proliferating coll nuclear antigen (PCNA) myocyte expression and histoputhologic features related to its occurrence were investigated in normal and diseased hearts of adult humans using both inimunohistochemical and Western blotting techniques. Ki67 Western blotting was also performed in the same samples used for PCNA blotting. Two hundred seventy-one endomyocardial biopsies, and 15 adult, 1 embryonic and 2 fetal hearts were studied. The biopsies were from normal donor hearts (n = 71), patients with cardiomyopathy and myocarditis (n = 64), and patients with transplantation with (n = 106) and without (n = 30) acute rejection of any grade. The 1S hearts were from 1 heart donor, and from patients with cardiomyopathy (n = S), valvular heart disease (n = 2), ischemic heart disease (n = 4), amyloidosis (n = 1) and transplantation with acuto rejection (n = 2). The PCNA labeling index was plotted against myocyte hypertrophy, inflammatory infiltrates and binucleation index. The PCNA labeling index ranged from 2 to 9% in embryonic and fetal hearts. PCNA was expressed by 1 to 2% of myocyte nuclei in 12% of normal heart biopsies, 1 to 5% of myocyte nuclei in 28% of cardiomyopathy and myocarditis biopsies, and by up to 8% of myocyte nuclei in 53% of biopsies of patients with transplantation, independently of the presence and degree of acute rejection. In the latter biopsies and in myocarditis, some inflammatory cells also showed PCNA expression. PCNA positive myocytes were both mono- and binucleated, and there was no correlation between binucleation and PCNA labeling indexes. Ki67 and PCNA blotting confirmed immunohistochemical results. The results show that few myocytes express PCNA in normal hearts. This expression is only detectable by immunohistochemical stains. The percentage of PCNA expressing myocytes increases in diseased hearts of any origin, so that it becomes detectable by both immunohistochemical and Western blotting techniques. Data from transplanted heart biopsies confirm that as in myocarditis, immunologic-inflammatory stimuli are likely powerful triggers of PCNA expression. Therefore, cardiac myocytes of adult humans can express proliferating cell markers, and this expression increases in hearts with hypertrophy or inflammatory reaction. (Am J Cardiol 1993;72:608-614) Embryonic and fetal hearts grow through proliferation of differentiated cardiac myocytes. A few days after birth, myocardial tissue loses its proliferative 'capacity' and soon becomes a 'non-dividing' tissue.[1,2] Growth of myocytes in neonatal rats can be divided into 3 different phases: hyperplastic, transitional and hypertrophic. Myocyte binucleation is considered an early marker of growth hypertrophy and could be the result of mitosis without cytokinesia.[3] Therefore, deoxyribonucleic acid (DNA) of non-dividing cells is probably renewed by mechanisms other than mitotic cell division. The biological half-life of myocyte DNA is estimated to be approximately 40 days with the labeled thymidine method.[4] Given the absence of mitotic division in the myocardium of adult humans,[1-4] the only methods available for investigating possible DNA renewal are those that study cell cycle phases.[4,5] Both thymidine[4] and bromodeoxiuridine incorporation[5] require in vivo administration, but there are no indications for administration of bromodeoxyuridine in cardiac disorders to increase susceptibility of cells to lethal effects of x-radiation, as in neoplastic diseases.[6] Conversely, immunohistochemical methods that detect cell cycle-related antigens can be safely and usefully employed. Examples include Ki67, which identifies a nuclear antigen expressed in all phases except GO,[7,8] and proliferating cell nuclear antigens (PCNA), which are similarly expressed in late G1, S, G2 and M phases of cell cycles.[9,10] The former can be detected only in frozen tissue, whereas the latter can be studied in formalin-fixed, paraffin-embedded samples, because it reacts with a formalin-resistant epitope of PCNA (cyclin). A recent experimental study performed in rat cardiomyocytes demonstrated PCNA messenger ribonucleic acid but not PCNA protein expression in nondividing adult cardiac muscle cells, suggesting post-transcriptional PCNA regulation.[11] To investigate proliferating cell markers in human adult cardiac myocytes and stimuli influencing their expression, we performed immunohistochemical and Western blotting studies using PCNA and Ki67 antibodies in normal and diseased hearts, including cardiomyopathies, other heart diseases and transplanted hearts. PCNA is a 36 KDa nuclear protein that has been identified as an auxiliary molecule of DNA polymerase [sigma].[9] PCNA labeling index correlates with flow cytometric determination of S phase fraction,[12] tritiated thymidine labeling index,[9,13] bromodeoxyuridine incorporation[13,14] and Ki67 labeling index.[15] METHODS Materials: Two embryonic, 1 fetal and 15 adult hearts, and 271 endomyocardial biopsies were investigated. Seventy-one biopsies were from normal donor hearts (22 female and 49 male; mean age 34.4 [+ or -] 13.5 years, range 14 to 61). The hearts had 129 [+ or -] 49 minutes (range 37 to 260) of ischemia between explantation from donor and transplantation. Sixty-four biopsies were from patients (17 women and 47 men; mean age 45 [+ or -] 12 years, range 20 to 62) with the clinical diagnosis of dilated cardiomyyopathy (n = 58), restrictive cardiomyopathy (n = 3), myocarditis (n = 1), Loeffler disease (n = 1) and hypertrophic cardiomyopathy (n = 1). Large right ventricular samples from normal and diseased hearts were also investigated with immunohistochemical and Western blotting methods (see later) to confirm small biopsy results. Finally, 136 biopsies were from transplanted hearts (Table I). All endomyocardial biopsies were perfomed according to the Stanford technique.[16] Four to 6 adequate samples for each procedure were fixed in 10% buffered formalin (20 minutes), dehydrated in a modified alcohol series (95% alcohol: 15 minutes, and 100% alcohol: 15 minutes) and xylene (15 minutes), and embedded in a single paraffin block.[17] For normal donor and idiopathic dilated cardiomyopathy biopsies, 45 sections were serially cut and consecutively collected on 15 slides, and stained at 3 cutting levels (every 75[mu]m) with hematoxylin-eosin and Masson's trichrome or Movat pentachrome. For biopsies from patients with transplantation, 120 sections were serially cut, consecutively collected on 40 slides and similarly stained at 6 cutting levels. Unstained sections were used for immunohistochemical studies. Hispathologic evaluation of endomyocardial biopsies: Normal donor biopsies were studied using previously reported methods and criteria.[18] Idiopathic dilated cardiomyopathy biopsies were evaluated following histopathologic parameters described previously.[19] Acute cardiac rejection was diagnosed according to Stanford criteria and grading.[20] We only distinguished between focal (type A) and diffuse (type B) moderate rejection, with special reference to extension of myocyte damage and necrosis.[21] In the present study, transplantation biopsies are reported with both original diagnosis and grade, and Working Formulation--International Society of Heart Transplantation new grading for acute rejection.[22] Light microscopy immunohistochemistry: Immunohistochemical staining was performed on sections consecutive to those stained with hematoxylin-eosin, Masson's trichrome and Movat pentachrome. Sections were deparaffinized and brought to Tris-phosphate-buffered saline solution (Tris-buffered saline 0.15 M, pH 7.35). After blocking endogenous peroxidase with 3% [H.sub.2][O.sub.2], and pretreatment with type XXVII protease (Sigma Chemicals, St. Louis) or trypsin, the slides were incubated overnight with the primary antisera. Immunohistochemical staining was performed with the peroxidase-antiperoxidase method[23] and avidin-biotin complex technique.[24] Diaminobenzidine (Sigma) was used as chromogen substrate. Specificity tests, performed by omission of the first layer, produced negative results. PCNA monoclonal antibodies were commercially obtained (Dako A/S, Denmark). The optimal working dilution was 1:300. Titration tests were performed on routinely fixed specimens, including normal (lymphatic and epithelial) and neoplastic (breast carrinomas, central nervous system neoplasms and bowel tumors). Quantitation of binucleated and proliferating cell nuclear antigen-labeled nuclei: The percentages of binucleated myocytes and immunolabeled nuclei were semiquantitatively evaluated in all samples using 25 X objective lens. Binucleation was evaluated in longitudinally cut myocytes. In cases with significant field-to-field variation, the highest and lowest scores were indicated. We used this method because no image analysis system can distinguish between myocyte and endothelial or interstitial cell nuclei. In addition, semiquantitative techniques have been reported to provide reproducible and useful results in other tissues.[12] Immunoblotting: We also used immunoblotting techniques on multiple samples to test the presence and specificity of anti-PCNA antibodies. The samples were from the following heart types: 1 normal donor (24-year-old man who died from cerebral trauma); 5 with idiopathic dilated cardiomyopathy; 4 with coronary artery disease; 2 with valvular heart disease; 1 explanted heart with amyloidosis; and transplanted hearts with acute rejection obtained at either retransplantation (n = 1) or autopsy (n = 1). All but 1 of the samples were from men in the age range of 24 to 58 years (mean 47.5 [+ or -] 10.4). Biopsy samples are usually too small to extract adequate amounts of protein for blotting. Methods were previously described in detail.[25] Polyacrylamide 10% gel electrophoresis was performed according to the Laemmly method.[26] Proteins were transferred to nitrocellulose according to Towbin et al.[27] The presence of Ki67 antigen (Ki67 monoclonal antibody, Dako A/S) was also tested in the samples used for PCNA blotting and for immunohistochemical stains by sodium dodecyl sulphate polyacrylamide gel electrophoresis with a low percentage (5%) acrylamide stab gel system.[28] The membranes were then incubated with the primary antibodies for 1 hour. Bound antibody was targeted with alkaline phosphatase conjugated with goat anti-mouse immunoglobulin G. Finally, bound alkaline phosphatase was visualized following the method of Leary et al.[29] Statistical analysis: To verify the presence of association between categoric variables (Table II), chi-square tests were performed, and C contingency coefficients were computed for the normal heart donor group, as well as for the cardiomyopathy group. The variable 'age' was transformed into 20-year interval classes for testing against other variables. For testing between ordinal variables, Kendall tau coefficients were also computed. RESULTS PCNA-immunolabeled nuclei were sharp and easily identified in both myocyte and interstitial cells. Only myocyte nuclei were considered. Nuclear staining pattern were both diffuse and finely reticular, and exhibited variable intensity. Immunohistochemical results in fetal hearts: Embryonic and fetal hearts had a high PCNA labeling index ranging from 2 to 9% (Figure 1). The highest scores were obtained from the interventricular septum and left ventricular walls. Immunohistochemical results in normal donor biopsies: PCNA labeling was detected in myocyte nuclei of 8 of 71 donor biopsies (11.27%). Few positive endothelial and interstitial mesenchymal cells were observed in 1 case. In the 8 positive cases, the PCNA labeling index ranged from 1 to 2%. Binucleated myocytes were observed in 50 of 71 biopsies (70.42%), and binucleation index ranged from 0 to 3%. Myocyte hypertrophy (transversal 0 >20 [mu]m) was found in 25 biopsies (35.2%), and some fibrosis in 24 (33.8%). No relation was observed between PCNA labeling, and age, myocyte hypertrophy and binucleation (Table II), because PCNA protein expression was detected in both mono--and binucleated myocytes (Figure 2). Immunohistochemical results in biopsies of patients with idiopathic dilated cardiomyopathy: Histopathologic study of the biopsies of patients with idiopathic dilated cardiomyopathy showed features consistent with cardiomyopathy in 31 cases (including 1 arrhythmogenic right ventricular disease), myocyte hypertrophy or interstitial fibrosis, or both, in 13, granulomatous myocarditis in 3, healing myocarditis in 2, isolated myocyte hypertrophy in 7, Loeffler endocardial disease in 1, endomyocardial fibrosis in 1, small vessel disease in 1, cardiac amyloidosis in 1, sparse lymphocytes with no hypertrophy or fibrosis in 1, and histologically normal myocardial tissue in 3. PCNA labeling index showed high field-to-field variation in the percentage of positive cells, ranging from 1 to 4% in positive cases. Binucleation index varied from 0 to 5%. The intensity and pattern of immunoreactivity were similar to those observed in normal donor biopsies, but positive immunoreaction occurred mostly (but not exclusively) in hypertrophic cardiomyopathy and huge, bizarre nuclei of idiopathic dilated cardiomyopathy biopsies (Figure 3). In myocarditis and the Loeffler case, some inflammatory cells had sparse labeled nuclei that were not counted. An association was found between age and binucleation index on the one hand (Kendall tau - 0.245), and between PCNA and binucleation index with a higher contingency coefficient on the other (Table II). Immunohistochemical results in transplanted heart biopsies: In this series, we detected a very high percentage of positive biopsies (53%). Grouping of these biopsies according to presence of acute cardiac rejection and degree of rejection itself revealed no difference between rejection-free biopsies (Figure 4, a, b and c) and those with mild (Figure 4d) or moderate Figure 5, a and b) rejection (Table I). Contrary to idiopathic dilated cardiomyopathy and noninflammatory diseases, and analogous to inflammatory diseases, interstitial inflammatory cells other than myocytes showed definite nuclear immunostaining. PCNA myocyte labeling index was higher in transplanted hearts than normal or idiopathic dilated cardiomyopathy hearts, reaching values as high as 8%. Immunoblotting results: Antibodies to PCNA recognized a 36 KDa-band polypeptide in immunoblotting studies of large samples from hearts with idiopathic dilated cardiomyopathy, ischemic heart disease, valvular heart disease, amyloidosis and acute rejection, whereas no bands were observed in normal heart samples. Negative immunoblotting findings in normal heart samples indicate that the method does not detect the small amounts of PCNA protein clearly shown by immunohistochemical study. Antibodies to Ki67 recognized a 354 KDa polypeptide not only in the same samples expressing PCNA (9 of 14 diseased hearts; 62.3%), but also in 3 additional cases (12 of 14; 85.7%). Comparison between different methods: Immunohistochemical stains detected single PCNA-positive nuclei, whereas blotting did not detect the very low protein amount present in normal hearts. The probability of finding PCNA immunoreactivity increased with sample size, so that PCNA expression was found in 40% of large versus 26% of small idiopathic dilated cardiomyopathy biopsies. In addition, PCNA expression was not influenced by preservation. When using Western blotting techniques on extracts from nonfixed tissue, we found that 40% of idiopathic dilated cardiomyopathy myocardial samples expressed PCNA. Some PCNA derived from myocyte nuclei, because immunohistochemical staining did not show labeling of interstitial or endothelial cell nuclei in idiopathic dilated cardiomyopathy samples. Finally, blotting with Ki67 revealed 80% of idiopathic dilated cardiomyopathy samples to be positive (Table III). The highest Ki67 expression found by blotting in diseased hearts was probably related to its large size and high molecular weight. DISCUSSION This is the first report documenting expression of PCNA protein in normal adult human myocytes. PCNA expression increases in different disorders primarily affecting myocardium, such as idiopathic dilated cardiomyopathy and myocarditis, and in transplanted hearts where myocardial tissue is subjected to chronic immunologic stimuli. This PCNA expression suggests the possibility that periodic DNA renewal occurs in human adult myocytes, and that expression rate can be influenced by hypertrophy and immune- or inflammatory-mediated stimuli. Therefore, although myocardium is a non-dividing tissue, mechanisms other than mitotic cell replication could intervene in DNA renewal in stimulated myocytes. The data provide new insights into myocardial expression of proliferating cell markers. Functionally normal adult myocardium: There is definite evidence that during fetal life cardiac muscle cells synthesize DNA and divide.[1,2,4] Our embryonic and fetal hearts did not show mitosis, but did show PCNA immunoreactivity. This is in accordance with blotting data reported by Marino et al.[11] The percentage of labeled myocytes (labeling index) after 24 hours of ([sup.3]H)thymidine incorporation is inversely related to heart growth, so that the labeling index is at a maximum during early fetal life, progressively reduces after birth and is negligible by the end of the third week.[4] The present results in normal donor biopsies are in accordance with data obtained from experimental animals. We found PCNA-labeled myocyte nuclei in 12% of normal biopsies. In the positive cases, the PCNA labeling index was very low (1 to 2%). Other studies investigating myocardial PCNA expression did not find any staining in adult cardiac myocytes.[10] These different results could be related to technical processing of biopsy samples. Fixation time can greatly alter detection of PCNA immunoreactivity. The short fixation time, together with previously described, modified processing methods[17] used in this study, could explain these differences. We did not find any significant correlation between PCNA protein expression and age, hypertrophy and binucleation index in the normal heart group. Binucleated cardiac myocytes, early indicators of growth hypertrophy,[3] are a frequent finding in normal adult human hearts, representing up to 3% of myocytes. In the present study, PCNA immunolabeling was detected in some binucleated myocytes, whereas it was not found in many other binucleated myocytes. Therefore, binucleation and PCNA protein expression are not necessarily related to each other. The negative results obtained by blotting with PCNA in normal hearts confirms that the amount of PCNA protein is too small to be detected by this technique. The negative results obtained in normal heart samples with Ki67 blotting could have 2 possible interpretations. The first possibility is that Ki67 is not expressed at al, whereas the second is that as with PCNA, the technique is not sufficiently sensitive to detect small amounts of Ki67 possibly expressed in normal hearts. The present PCNA blotting results are in accordance with those reported by Marino et al[11] in their Western blotting study of adult experimental hearts. Conversely, immunohistochemical techniques proved to be more sensitive than did blotting, because they detected PCNA protein expression even in single cells and were also more useful for precisely defining labeled cell phenotype. Accordingly, very low but definite PCNA expression in functionally normal, adult human hearts suggests that there is a low but constant rate of DNA synthesis, indicating the possibility of amitotic DNA renewal. Diseased adult hearts: Percentages of PCNA immunolabeling in this series varied according to pathologic entities, reaching a maximal value in myocarditis and the lowest percentages in cardiomyopathies; in the former, positive myocyte nuclei were found in all biopsies, whereas in the latter, the incidence of positive cases was twice that of normal hearts. The paucity of cases with other, rarer disorders prevents consideration of such disorders. However, there is a trend toward increasing expression of PCNA from normal to diseased hearts with abnormal stimuli, such as inflammation or hypertrophy. Previous studies indicated that as diseased hearts increase in size and age, the ploidy of the cardiac muscle cells increases.[30-32] Those data suggest that some new DNA synthesis occurs in human adult cardiac myocytes, and are in accordance with our finding of PCNA positivity in cases with hypertrophy of any origin and nature (i.e., primary, such as in cardiomyopathy, or secondary, such as that of valvular heart disease). Binucleation correlated with patient age, suggesting that it can be an age-related feature (as can hypertrophy).[18] In addition, in cardiomyopathy hearts, binucleation index correlated with PCNA nuclear immunolabeling, although some positive nuclei were single. This result could be consistent with abnormal DNA renewal or repair[33] in huge nuclei often observed in cardiomyopathies.[19] With respect to normal control cases, PCNA overexpression by myocyte nuclei in the different primary or secondary noninflammatory disorders, as well as Ki67 expression found by blotting, suggests that proliferating cell antigen expression increases in hearts with stimuli of any origin and type. The actual significance of PCNA immunolabeling in myocarditis is not clear. Inflammation could stimulate myocyte DNA renewal, as well as cause cardiac damage needing DNA repair.[33] Accordingly, myocytes could respond to inflammatory stimuli by regenerating their sarcoplasmatic and sarcolemmal components after DNA renewal or repair. In any PM of myocardial inflammatory injury, nuclei are the last cell components to die. Transplanted heart biopsies: The highest percentages of PCNA protein expression, together with the highest PCNA labeling index, were found in biopsies from transplanted hearts. The presence of acute rejection of any degree (mild or moderate) did not influence PCNA expression, because positive nuclei were observed in biopsies both with and without acute rejection. The PCNA labeling index was also similar in rejection and nonrejection groups, suggesting that permanent immunologic stimuli, rather than grade, probably influence expression of DNA renewal markers. The presence of labeled nuclei in the interstitial inflammatory or mesenchymal cells was not related to myocyte nuclei labeling, because the latter was found in areas both with and without infiltrates. The positive blotting results for both PCNA and Ki67 in transplanted hearts with acute rejection could be due to both myocytes and inflammatory or interstitial positive cells detected by immunohistochemistry. However, immunohistochemical study showed that at least part of immunoreactivity is definitely due to myocyte nuclei PCNA expression. The high expression of cell proliferation markers in denervated, transplanted hearts could be positive for myocardial well-being. However, we are still far from understanding the mechanisms regulating myocardial cell replication or renewal. The very recent demonstration that PCNA is needed for DNA excision repair[33] suggests an alternative explanation for PCNA expression in normal and diseased myocardium in humans. In conclusion, the unexpected expression of cell proliferation markers such as PCNA and Ki67 in diseased human adult hearts suggests that myocardium may increase its DNA renewal or repair rate as a result of inflammatory or immunologic injuries and of stimuli triggering primary or secondary hypertrophy. Aknowledgment: We thank Emanuele Porcu for technical assistance, and Linda D'Arrigo for English revision. [1.] Peterson RO, Baserga R. Nucleic acid and protein synthesis in cardia muscle of growing and adult mice. Exp Cell Res 1965;40:340-352. [2.] Rumayantsev PP. Interrelations of the proliferation and differentiation processes during cardiac myogenesis and regeneration. Int Rev Cytol 1977;51:187-273. [3.] Clubb FJ, Bishop SP. Formation of binucleated myocardial cells in the neonatal rat. Lab Invest 1984;50:571-577. [4.] Pelc SR. Labelling of DNA and cell division in so called non-dividing tissues. J Cell Biol 1964;22:21-28. [5.] Sugihara H, Hattori T, Fukuda M. Immunohistochemical detection of bromodeoxyuridine in formalin-fixed tissues. Histochemistry 1986;85:193-195. [6.] Kriss JP, Maruyama Y, Tung LA, Bond SB, Revesz L. The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine and 5-iododeoxycytidine in man. Cancer Res 1963;23:260-268. [7.] Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715. [8.] Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489-503. [9.] Mathews MB, Bernstein RM, Franza BR Jr, Garrels JI. Identity of the proliferating cell nuclear antigen and cyclin. Nature 1984;309:374-376. [10.] Hall PA, Levison DA, Woods AL, Yu CCW, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162:285-294. [11.] Marino TA, Haldar S, Williamson EC, Beaverson K, Walter RA, Marino DR, Beatty C, Lipson KE. Proliferating cell nuclear antigen in developing and adult rat cardiac muscle cells. Circ Res 1991;69:1353-1360. [12.] Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti PCNA/cyclin monoclonal antibodies in fixed, embedded tissue. Comparison with flow cytometric analysis. Am J Pathol 1989;134:733-739. [13.] Buttersby S, Andersen TJ. Correlation of proliferative activity in breast tissue using PCNA/cyclin. Hum Pathol 1990;21:781. [14.] Coltrera MC, Gown AM. PCNA/cyclin expression and BrdU uptake define different cell subpopulation in different cell lines. J Histochem Cytochem 1991; 39:23-30. [15.] Levison DA, Hall PA, Woods AL, Yu C, Barnes DM, Wasseem N, Lane DP. Evaluation of PCNA (proliferating cell nuclear antigen) immunostaining as a marker of cell proliferation in formalin-fixed paraffin-embedded tissues (abstr). J Pathol 1990;161:341. [16.] Caves PK, Stinson EB, Billingham ME, Shumway NE. Percutaneous transvenous endomyocardial biopsy in human heart recipients. Ann Thorac Surg 1973; 16:325-336. [17.] Arbustini E, Grasso M, Diegoli M, Bramerio M, Scotti Foglieni A, Albertario M, Martinelli L, Gavazzi A, Goggi C, Campana C, Vigano M. Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical and immunoblotting study. Am J Pathol 1991;139:707-715. [18.] Arbustini E, Gavazzi A, Pozzi R, Pucci A, Grasso M, Diegoli M, Campana C, Graziano G, Martinelli L, Goggi C, Montemartini C, Vigano M. Endomyocardial biopsy of normal heart before cardiac transplantation. A morphologic and morphometric study in 97 cases. Am J Cardiovasc Pathol 1992;4:1-8. [19.] Arbustini E, Gavazzi A, Pozzi R, Grasso M, Pucci A, Campana C, Graziano G, Martinetti M, Cuccia MC, Martinelli L, Salvaneschi L, Montemartini C, Vigano M. The morphologic spectrum of dilated cardiomyopathy and its relation to immune-response genes. Am J Cardiol 1989;64:991-995. [20.] Billingham Me. Diagnosis of cardiac rejection by endomyocardial biopsy. Heart Transplant 1981;1:25-29. [21.] Arbustini E, Grasso M, Diegoli M, Gavazzi A, Campana C, Martinelli L, Goggi C, Pucci A, Grossi P, Ippoliti C, Vigano M. La biopsia endomiocardica nel paziente cardiotrapiantato: stato dell'arte. G Ital Cardiol 1991;21:1107-1123. [22.] Billingham ME, Cary NRB, Hammond ME, Kemnitz J, Marboe C, McA]lister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 1990;9:587-593. [23.] Stemberger LA. The unlabelled antibody enzyme peroxidase-antiperoxidase (PAP) method. In: Stemberger LA, ed. Immunocytochemistry. New York: John Wiley, 1979:104-169. [24.] Hsu SM, Rainel L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981;29:577-580. [25.] Arbustini E, Pucci A, Grasso M, Diegoli M, Pozzi R, Gavazzi A, Graziano G, Campana C, Goggi C, Martinelli L, Silini E, Specchia G, Vigano M, Solcia E. Expression of natriuretic peptide in ventricular myocardium of failing human hearts and its correlation with the severity of clinical and hemodynamic impairment. Am J Cardiol 1990;66:973-980. [26.] Laemmly UK. Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature 1970;227:680-685. [27.] Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4354. [28.] Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-873. [29.] Leary JJ, Brigatti DJ, Ward DC. Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized tp DNA or RNA immobilized on nitrocellulose: bioblots. Proc Natl Acad Sci U S A 1983;80:4045-4049. [30.] Anversa P, Olivetti G, Loud AV. Morphometric study of early postnatal development in the left and right ventricular myocardium of the rat. Circ Res 1980;46:495-502. [31.] Brodsky WJ, Arefyeva AM, Uryvaeva IV. Mitotic polyploidization of mouse heart myocytes during the first postnatal week. Cell Tissue Res 1980;210:133-144. [32.] Sandritter W, Scomazzoni G. Deoxyribonucleic acid content (Feulgen photometry) and dry weight (interference microscopy) of normnal and hypertrophic heart muscle fibres. Nature 1984;202:100-101. [33.] Shivij MKK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992;69:367-374. From the Pathology, Cardiac Surgery, and Cardiology Departments, Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS, Policlinico San Matteo, Universita di Pavia, Pavia, Italy. This study was supported by grants 'Trapianto Cardiaco' and 'Trapianto Cuore-Polmoni' from Health Ministry to IRCCS, Policlinico San Matteo, Pavia-Ricerche Finalizzate 1989-1990. Manuscript received October 23, 1992; revised manuscript received March 8, 1993, and accepted March 19. Address for reprints: Eloisa Arbustini, MD, Dipartimento di Patologia Umana ed Ereditaria, Sezione di Anatomia Patologica, Via Forlanini 14, 27100 Pavia, Italy.
- Published
- 1993
12. Morphologic changes induced by acetylcholine infusion in normal and atherosclerotic coronary arteries
- Author
-
Arbustini, Eloisa, Grasso, Maruizia, Diegoli, Marta, Bellini, Ornella, Ghio, Stefano, DeServi, Stefano, Martinelli, Luigi, Vigano', Mario, and Specchia, Giuseppe
- Subjects
Acetylcholine -- Physiological aspects ,Coronary arteries -- Dilatation ,Atherosclerosis -- Physiological aspects ,Health - Abstract
Low doses of acetylcholine induce 'endothellum-dependent' dilatation in normal coronary arteries and constriction of diseased vessels. This study investigated morpholoigic changes induced by perfusion of normal and diseased coronary arteries with low and high doses of acutylchollne. Vessels were excised from a series of beating hearts explanted at transplantation for idiopathic dilated cardliomyopathy and coronary artery dim. Coronary arteries from other explanted hearts, perfused with saline solution under similar conditions were taken as control. Samples were studied using conventional histopathologic and immuno-histochemical methods. Coronary arteries were grouped according to presence or absence of his tologically detectable structural modifications of any type and extent. Low doses of acetylcholine Induced changes In all but 1 structurally diseased coronary artery, whereas no change was induced in any but 1 histologically normal coronary artery. High doses of acetylcholine induced contraction changes In both normal diseased vessels. Changes observed in the wall of the contracted vessels were: (1) endothelial cell contraction with protruding nuclei and detachment of their intercellular junctions with exposure of subject collaget to flow, (2) contraction of plaque smooth muscle cells, (3) formation of cushions protruding Into vessel lumens causing blunt microchannels. Contraction in both intimal and plaque culls occurred even in diseased vessel segments with intimal denudation. These effects seemed to be dose-dependent in structurally normal vessels because low doses of acetyicholine did not produce any morphologically detectable changes in histologically normal coronary arteries, while low domes of acetyicholine induced similar reactions in vessels affected by both atherosclerosis and subintimal flbrocellular thickening. (Am J Cardiol 1993;71:1382-1390)
- Published
- 1993
13. Search for coxsackievirus B3 RNA in idiopathic dilated cardiomyopathy using gene amplification by polymerase chain reaction
- Author
-
Grasso, Maurizia, Arbustini, Eloisa, Silini, Enrico, Diegoli, Marta, Percivalle, Elena, Ratti, Giulio, Bramerio, Manuela, Gavazzi, Antonello, Vigano, Mario, and Milanesi, Gabriele
- Subjects
Coxsackieviruses -- Diagnosis ,Cardiomyopathy, Dilated -- Diagnosis ,Gene amplification -- Usage ,Health - Abstract
A polymerase chain reaction (PCR) amplification assay was developed to detect Coxsackievirus B3 ribonucleic acid (RNA) in blood and myocardial tissue of explanted hearts from 40 patients who underwent cardiac transplantation and in 1 normal heart. Twenty-one patients were affected duration dilated cardiomyopathy of different duration and 19 by coronary artery disease. Coxsackievirus B3 in vitro infected Vero cells and cells infected by related human enteroviruses (Coxsackievirus B2, B4, and poliovirus 1) were used as reaction controls. PCR was performed using 4 pairs of primers homologous to Coxsackievirus B3 sequences. Three sets were located in regions of the genome conserved at nucleotide level between several entervirus species (replicase gene, 5' noncoding region), while one was located in a Coxsackievirus B3-specific region (VP1 gene). Total RNA was prepared by acid guanidinium isothyocyanate extraction from tissue stored frozen at -80 [degrees] C. One microgram of total RNA was retrotranscribed with either antisense primer or with random hexanucleotide primers and then subjected to 40 cycles of amplification. PCR products were separated byd electrophoresis on a 10% polyacrilamide gel, electrotransferred to a nylon membrane and then hybridized to oligonucleotide probes specific for the coxsackievirus B3 genome radiolabeled with radioactive isotope of phosphorous. All pairs of primers yielded specific amplification products when tested on Coxsackievirus B3-infected Vero cells, with a sensitivity of 1 infected cell out of [10.sup.5] to [10.sup.6] cells starting from 1 [mu]g total RNA. Primer sets for regions of Coxsackievirus B3 genome highly conserved between related enteroviral species gave positive amplification also when challenged with RNA from cells infected by Coxsackievirus B2, B4 and poliovirus 1. The VP1 gene primer set produced positive amplification only with RNA of Coxsackievirus B3-infected cells. Coxsackievirus B3-specific amplification products were distinguished from those of related enteroviruses by hybridization with specific oligoprobes. However, Coxsackievirus B2, B4 and poliovirus 1-specific PCR products showed positive hybridization if probed with Coxsackievirus B3 genomic probes. All total RNAs from blood and myocardial samples examined by our PCR assay failed to reveal any amplification product that could be related to Coxsackievirus B3 or to enteroviruses in general, after gel electrophoresis and low stringency Southern blot hybridization with the Coxsackievirus B3 specific oligoprobes or the Coxsackievirus B3 genomic probes. The negative results obtained in our series question the hypothesized widespread persistence of enteroviral RNA in hearts with idiopathic dilated cardiomyopathy.
- Published
- 1992
14. H and L ferritins in myocardium in iron overload
- Author
-
Arbustini, Eloisa, Grasso, Maurizia, Rindi, Guido, Arosio, Paolo, Gavazzi, Antonello, Diegoli, Marta, Bramerio, Manuela, Levi, Sonia, and Barosi, Giovanni
- Subjects
Ferritin -- Physiological aspects ,Iron in the body -- Physiological aspects ,Heart muscle -- Physiological aspects ,Health - Published
- 1991
15. Coronary atherosclerotic plaques with and without thrombus in ischemic heart syndromes: a morphologic, immunohistochemical, and biochemical study
- Author
-
Arbustini, Eloisa, Grasso, Maurizia, Diegoli, Marta, Pucci, Angela, Bramerio, Manuela, Ardissino, Diego, Angoli, Luigi, de Servi, Stefano, Bramucci, Ezio, Mussini, Antonio, Minzioni, Gaetano, Vigano, Mario, and Specchia, Giuseppe
- Subjects
Thrombosis -- Development and progression ,Coronary heart disease -- Physiological aspects ,Atherosclerotic plaque -- Development and progression ,Health - Abstract
Ischemic syndromes are a collection of disorders in which the heart muscle does not receive an adequate supply of blood. Atherosclerosis, in which the arteries of the heart are partially blocked by fat-laden lesions, is very common in ischemic heart disease, but it is also common among people without ischemic heart disease. Ischemic heart disease may be stable or unstable. An example of a stable ischemic condition is stable angina, in which drugs designed to relax the blood vessels and improve blood flow often control the problem. Unstable ischemic syndromes include unstable angina and myocardial infarction (heart attack). These unstable conditions appear to be associated with the formation of blood clots, or thrombi, within the arteries of the heart. The formation of these blood clots seems to begin in an atherosclerotic lesion. Since atherosclerosis is so common, it is important to determine why some atherosclerotic conditions are stable and lead to only relatively benign disease while others are unstable and are more likely to result in heart attack or sudden death. To evaluate the distinctions among different patients with atherosclerosis, samples of artery tissue were examined from patients with stable, unstable, and nonischemic disease. These specimens were obtained during autopsy or surgery. It was found that extensive narrowing (stenosis) of the coronary arteries was common; it was present in 90 percent of cases of stable and unstable disease. Furthermore, stenosis was found in about half the patients with nonischemic disease. Researchers observed, however, that the composition of the plaque seemed to influence the likelihood of clot formation within the artery. Thrombi were more likely to be associated with atherosclerotic lesions that were mostly fatty pulp, that is, pultaceous. In contrast, thrombi were less likely to be associated with atherosclerotic lesions that were mostly fibrous. Since a primary step in the development of a thrombus is the adherence of platelets (cells involved in clotting) to the surface of the atherosclerotic lesion, it would seem that the characteristics of this surface play a major role in the progression of thrombosis. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1991
16. Expression of natriuretic peptide in ventricular myocardium of failing human hearts and its correlation with the severity of clinical and hemodynamic impairment
- Author
-
Arbustini, Eloisa, Pucci, Angela, Grasso, Maurizia, Diegoli, Marta, Pozzi, Roberto, Gavazzi, Antonello, Graziano, Gabriella, Campana, Carlo, Goggi, Claudio, Martinelli, Luigi, Silini, Enrico, Specchia, Guiseppe, Vigano, Mario, and Solcia, Enrico
- Subjects
Heart failure -- Complications ,Heart failure -- Physiological aspects ,Heart ventricle, Left -- Physiological aspects ,Natriuretic peptides -- Physiological aspects ,Health - Abstract
Atrial natriuretic peptide (ANP) is a substance secreted by the atrium of the heart in response to stretching of cardiac tissue (such as occurs during hypertensive episodes or congestive heart failure). It causes excretion of sodium in the urine, dilation of the blood vessels, and other physiological responses that tend to reduce the workload of the heart. Human atrial myocytes (muscle cells) have been shown to contain ANP. In heart failure, ventricular myocytes also appear to contain and secrete ANP. This results from an induction (turning on) of the normally inactive ventricular ANP gene. To investigate the factors involved in the re-expression of the ANP gene in failing human hearts, a microscopic study was undertaken to analyze muscle tissue from 87 healthy hearts, one heart from a patient with hepatitis B, 151 hearts from patients with dilated cardiomyopathy (a type of heart disease), 26 explanted hearts with dilated cardiomyopathy, and 31 explanted hearts with ischemic heart disease (cardiac damage resulting from decreased blood flow). Hearts were treated with specific stains to detect the presence of ANP. The ventricles of normal hearts were completely devoid of ANP. Ventricular ANP was found in 30 to 60 percent of the ventricles of the failing hearts, and the presence and extent of ventricular ANP was not related to the type of heart disease. However, there was a correlation between the amount of ventricular ANP and both the severity of the disease symptoms and several physiological indices of cardiovascular dysfunction. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
17. Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center.
- Author
-
Garcia-Etienne, Carlos A., Ferrari, Alberta, Della Valle, Angelica, Lucioni, Marco, Ferraris, Elisa, Di Giulio, Giuseppe, Squillace, Luigi, Bonzano, Elisabetta, Lasagna, Angioletta, Rizzo, Gianpiero, Tancredi, Richard, Scotti Foglieni, Andrea, Dionigi, Francesca, Grasso, Maurizia, Arbustini, Eloisa, Cavenaghi, Giorgio, Pedrazzoli, Paolo, Filippi, Andrea R., Dionigi, Paolo, and Sgarella, Adele
- Subjects
SENTINEL lymph node biopsy ,AXILLARY lymph node dissection ,HORMONE receptor positive breast cancer ,BREAST cancer ,AXILLA ,SENTINEL lymph nodes ,BREAST ,HORMONE receptors - Abstract
The surgical approach to the axilla in breast cancer has been a controversial issue for more than three decades. Data from recently published trials have provided practice-changing recommendations in this scenario. However, further controversies have been triggered in the surgical community, resulting in heterogeneous diffusion of these recommendations. The development of clinical guidelines for the management of the axilla in patients with breast cancer is a work in progress. A multidisciplinary team discussion was held at the research hospital Policlinico San Matteo from the Università degli Studi di Pavia with the aim to update recommendations for the management of the axilla in patients with breast cancer. An evidence-based approach is presented. Our multidisciplinary panel determined that axillary dissection after a positive sentinel lymph node biopsy may be avoided in cN0 patients with micro/macrometastasis to ≤2 sentinel nodes, with age ≥40y, lesions ≤3 cm, who have not received neoadjuvant chemotherapy and have planned breast conservation (BCS) with whole breast radiotherapy (WBRT). Cases with gross (>2 mm) ECE in SLNs are evaluated on individual basis for completion ALND, axillary radiotherapy or omission of both. Patients fulfilling the criteria listed above who undergo mastectomy, may also avoid axillary dissection after multidisciplinary discussion of individual cases for consideration of axillary irradiation. Women 70 years or older with hormone receptors positive invasive lesions ≤3 cm, clinically negative nodes, and serious or multiple comorbidities who undergo BCS with WBRT, may forgo axillary staging/surgery (if mastectomy or larger tumor, comorbidities and life expectancy are taken into account). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients
- Author
-
Garnier, Sophie, Hengstenberg, Christian, Lamblin, Nicolas, Dubourg, Olivier, De Groote, Pascal, Fauchier, Laurent, Trochu, Jean-Noël, Arbustini, Eloisa, Esslinger, Ulrike, Barton, Paul J., Meder, Benjamin, Katus, Hugo, Frese, Karen, Komajda, Michel, Cook, Stuart A., Isnard, Richard, Tiret, Laurence, Villard, Eric, and Charron, Philippe
- Published
- 2015
- Full Text
- View/download PDF
19. Correlating Pathology to Imaging: Improved Insights Into Peripheral Artery Disease?
- Author
-
Arbustini, Eloisa, Urtis, Mario, Prati, Francesco, and Chandrashekhar, Y.
- Published
- 2019
- Full Text
- View/download PDF
20. Cardiac Phenotypes in Hereditary Muscle Disorders: JACC State-of-the-Art Review.
- Author
-
Arbustini, Eloisa, Di Toro, Alessandro, Giuliani, Lorenzo, Favalli, Valentina, Narula, Nupoor, and Grasso, Maurizia
- Abstract
Hereditary muscular diseases commonly involve the heart. Cardiac manifestations encompass a spectrum of phenotypes, including both cardiomyopathies and rhythm disorders. Common biomarkers suggesting cardiomuscular diseases include increased circulating creatine kinase and/or lactic acid levels or disease-specific metabolic indicators. Cardiac and extra-cardiac traits, imaging tests, family studies, and genetic testing provide precise diagnoses. Cardiac phenotypes are mainly dilated and hypokinetic in dystrophinopathies, Emery-Dreifuss muscular dystrophies, and limb girdle muscular dystrophies; hypertrophic in Friedreich ataxia, mitochondrial diseases, glycogen storage diseases, and fatty acid oxidation disorders; and restrictive in myofibrillar myopathies. Left ventricular noncompaction is variably associated with the different myopathies. Conduction defects and arrhythmias constitute a major phenotype in myotonic dystrophies and skeletal muscle channelopathies. Although the actual cardiac management is rarely based on the cause, the cardiac phenotypes need precise characterization because they are often the only or the predominant manifestations and the prognostic determinants of many hereditary muscle disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
21. Systemic cause of unstable atherosclerotic plaques
- Author
-
Meschia, James F, Violi, Francesco, Loffredo, Lorenzo, Cortellaro, Michele, Cofrancesco, Elisabetta, Arbustini, Eloisa, Gabrielli, Livio, Tremoli, Elena, and Rothwell, P M
- Subjects
Atherosclerosis -- Physiological aspects ,Carotid artery diseases -- Physiological aspects ,Heart attack -- Risk factors - Published
- 2000
22. Diagnostic Criteria of Left Ventricular Dysfunction in Patients With Myotonic Dystrophy Type 1.
- Author
-
Di Toro, Alessandro, Giuliani, Lorenzo, Serio, Alessandra, and Arbustini, Eloisa
- Published
- 2020
- Full Text
- View/download PDF
23. When Genes, More Than Phenotype, Identify Different Diseases: The Case of Nonsyndromic HTAA/D.
- Author
-
Arbustini, Eloisa, Giuliani, Lorenzo, and Di Toro, Alessandro
- Subjects
- *
GENETICS , *AORTIC valve , *PATHOGENIC microorganisms , *ECHOCARDIOGRAPHY , *CONNECTIVE tissues , *PHENOTYPES , *THORACIC aneurysms , *DISSECTING aneurysms - Published
- 2018
- Full Text
- View/download PDF
24. Non-specific gastrointestinal features: Could it be Fabry disease?
- Author
-
Hilz, Max J., Arbustini, Eloisa, Dagna, Lorenzo, Gasbarrini, Antonio, Goizet, Cyril, Lacombe, Didier, Liguori, Rocco, Manna, Raffaele, Politei, Juan, Spada, Marco, and Burlina, Alessandro
- Abstract
Non-specific gastrointestinal symptoms, including pain, diarrhoea, nausea, and vomiting, can be the first symptoms of Fabry disease. They may suggest more common disorders, e.g. irritable bowel syndrome or inflammatory bowel disease. The confounding clinical presentation and rarity of Fabry disease often cause long diagnostic delays and multiple misdiagnoses. Therefore, specialists involved in the clinical evaluation of non-specific upper and lower gastrointestinal symptoms should recognize Fabry disease as a possible cause of the symptoms, and should consider Fabry disease as a possible differential diagnosis. When symptoms or family history suggest Fabry disease, in men, low alpha-galactosidase A enzyme levels, and in women, specific Fabry mutations confirm the diagnosis. In addition to symptomatic treatments, disease-specific enzyme replacement therapy with recombinant human alpha-galactosidase A enzyme or chaperone therapy (migalastat) in patients with amenable mutations can improve the disease, including gastrointestinal symptoms, and should be initiated as early as possible after Fabry disease has been confirmed; starting enzyme replacement therapy at as young an age as possible after diagnosis improves long-term clinical outcomes. Improved diagnostic tools, such as a modified gastrointestinal symptom rating scale, may facilitate diagnosing Fabry disease in patients with gastrointestinal symptoms of unknown cause and thus assure timely initiation of disease-specific treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Targeted Imaging for Cell Death in Cardiovascular Disorders.
- Author
-
Shekhar, Aditya, Heeger, Peter, Reutelingsperger, Chris, Arbustini, Eloisa, Narula, Navneet, Hofstra, Leonard, Bax, Jeroen J., and Narula, Jagat
- Abstract
Cell death is desirable in cancer cells and undesirable in organs with limited regenerative potential, like the heart. Cell death comes in many forms, but only apoptosis and to a lesser degree necrosis is currently relevant to the clinical imager. Noninvasive imaging of cell death is an attractive option to understand pathophysiology, track disease activity, and evaluate response to intervention. Apoptosis seems to be the most promising target for imaging cell death, because it could be reversible and might be modulated with interventions. Molecular, nuclear, optical, or magnetic resonance imaging–based methods have been developed to identify intermediate steps in the apoptosis cascade. Animal studies show promising results for noninvasive imaging in various cardiovascular diseases. Human studies have shown feasibility, but clinical use is yet inconclusive. Newer technologies offer promise, especially for tracking apoptosis in evaluation of novel therapeutic interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Functionally Incomplete Re-Endothelialization of Stents and Neoatherosclerosis.
- Author
-
Arbustini, Eloisa, Favalli, Valentina, and Narula, Jagat
- Published
- 2017
- Full Text
- View/download PDF
27. Simplified mitral valve repair in pediatric patients with connective tissue disorders.
- Author
-
Vricella, Luca A., Ravekes, William A., Arbustini, Eloisa, Jaquiss, Robert D.B., Mavroudis, Constantine, Dietz, Harry C., Jacobs, Marshall L., Hibino, Narutoshi, and Cameron, Duke E.
- Abstract
Background In pediatric patients with connective tissue disorders (CTDs), early cardiac presentation often involves severe mitral regurgitation (MR) associated with severe bileaflet prolapse and, less frequently, aortic root enlargement. We adopted a simplified repair to address MR and prevent systolic anterior motion (SAM) in this unique group of patients. Materials and Methods Retrospective review of clinical and echocardiographic data of all pediatric patients (age < 18 years) with CTD and MR undergoing simplified repair at 3 institutions (2000-2014). Results Eighteen children who underwent surgery for severe MR and bileaflet prolapse were identified. All were treated with ring annuloplasty and Alfieri edge-to-edge repair. Median age and weight were 8.2 years (range, 0.4-17.2 years) and 24.9 kg (5.6-63.3 kg), respectively. Median left ventricular end diastolic dimension median z score was 4.9 (2.1-11.9). One patient died (5.6%), and there were no other major complications. Among survivors, 94.4% had mild regurgitation or less, with no stenosis or SAM at median clinical follow-up of 2.4 years (range, 0-13.9 years). Median left ventricular end-diastolic dimension z score regressed to 1.3 (−0.5 to 4.3). Conclusions In pediatric patients with CTD and severe MR, a simplified approach is associated with intermediate-term competence, absence of SAM or significant stenosis, and regression of left ventricular enlargement. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Left Ventricular Noncompaction: A Distinct Genetic Cardiomyopathy?
- Author
-
Arbustini, Eloisa, Favalli, Valentina, Narula, Nupoor, Serio, Alessandra, and Grasso, Maurizia
- Subjects
- *
CARDIOMYOPATHIES , *LEFT heart ventricle diseases , *CONGENITAL heart disease , *MORPHOLOGY , *RYANODINE receptors , *GENETIC counseling - Abstract
Left ventricular noncompaction (LVNC) describes a ventricular wall anatomy characterized by prominent left ventricular (LV) trabeculae, a thin compacted layer, and deep intertrabecular recesses. Individual variability is extreme, and trabeculae represent a sort of individual "cardioprinting." By itself, the diagnosis of LVNC does not coincide with that of a "cardiomyopathy" because it can be observed in healthy subjects with normal LV size and function, and it can be acquired and is reversible. Rarely, LVNC is intrinsically part of a cardiomyopathy; the paradigmatic examples are infantile tafazzinopathies. When associated with LV dilation and dysfunction, hypertrophy, or congenital heart disease, the genetic cause may overlap. The prevalence of LVNC in healthy athletes, its possible reversibility, and increasing diagnosis in healthy subjects suggests cautious use of the term LVNC cardiomyopathy, which describes the morphology but not the functional profile of the cardiomyopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. Radiation Therapy for Head and Neck Cancer and Angioneogenesis: Good for Cancer, Bad for Carotids?
- Author
-
Arbustini, Eloisa, Kodama, Takahide, and Favalli, Valentina
- Published
- 2016
- Full Text
- View/download PDF
30. The morphologic spectrum of dilated cardiomyopathy and its relation to immune-response genes
- Author
-
Arbustini, Eloisa, Gavazzi, Antonello, Pozzi, Roberto, Grasso, Maurizia, Pucci, Angela, Campana, Carlo, Graziano, Gabriella, Martinetti, Miryam, Cuccia, Mariaclara, Salvaneschi, Laura, Martinelli, Luigi, Montemartini, Carlo, and Vigano, Mario
- Subjects
HLA histocompatibility antigens -- Research ,Cardiomyopathy -- Genetic aspects ,Heart -- Biopsy ,Cardiomyopathy -- Causes of ,Health - Abstract
Endomyocardial biopsies from 174 patients with dilated cardiomyopathy (DC) were examined. Eight patients with histologically proven myocarditis were excluded from the study. A peculiar pattern of oversized and bizarre nuclei was observed in only some of the remaining patients. Two groups were identified: those with and without this feature (groups A and B, respectively). Myocyte width, nuclear diameter and nuclear/sarcoplasmic ratio were significantly higher in group A. The mean respective values were 36 [+ or -] 5 [mu], 14 [+ or -] 3 [mu] and 0.41 [+ or -] 0.08 for group A versus 20 [+ or -] [mu], 7 [+ or -] 2 [mu] and 0.37 [+ or -] 0.08 for group B. interstitial fibrosis was similarly present in groups A and B. Endocardial thickness was significantly increased in all patients, with group A showing the highest mean value. The morphologic features showed no correlation with the clinical condition of the patients at time of presentation. HLA typing was performed in 50 consecutive patients, 38 from group A and 12 from group B. DR4 and DR5 antigens were significantly more frequent in DC patients than in a normal population control (400 blood donors), while DR3 was less frequent. Group A was more strongly associated with the DR5 antigen than group B (55.3 vs 25.0%, respectively). it was less strongly associated with the DR4 antigen compared with group B (21.5 vs 41.7%, respectively). No difference was observed between the 2 groups concerning negative association with the DR3 antigen. Endemyocardial biopsies from DC patients reveal marked morphologic changes from patient to patient. The histopathologic identification of 2 distinct DC groups with different HLA marker associations suggests that immune-response genetic factors may play a role in the histopathologic expression of the disease. (Am J Cardiol 1989;64:991-995), Dilated cardiomyopathy (DC) is a disease of the heart muscle in which the muscle cells (myocytes) degenerate and fibrous elements invade the tissue causing the wall to thicken. Genetic factors have been suggested as one possible cause. In particular, the association of specific human leukocyte antigens (HLA), molecules present on the surface of blood cells of every individual, with DC has been proposed. Fifty out of 166 patients diagnosed with DC on the basis of cardiac biopsy also provided blood samples for HLA determination. Biopsies were evaluated using the light microscope and measurements were of myocyte width (average width of the heart cell), various cell nuclei dimensions including diameter, extent of fibrosis (or presence of fibrous tissue), thickness of the heart wall, and other related variables. Blood from 400 hundred healthy blood donors was used to determine HLA antigen frequencies in the general population for comparison with the group with DC. The most important finding regarding muscle cells from DC patients was the presence of very large, abnormal cell nuclei. The magnitude of these changes, however, was not correlated with extent of symptoms or duration of the disease. The 60 percent of patients who had this abnormality constituted Group A, while the remainder made up Group B. When DC patients were compared with the population as a whole, they were found to display HLA antigen subtypes DR4 and DR5 more often, with no difference for DR3. Among DC patients as a group, HLA antigen subtype DR4 was more frequent in Group B than Group A; subtype DR5, on the other hand, was more frequent in Group A patients. The lack of correlation between abnormal cells and disease progression argued against interpreting these changes as a pathological response to failure of the heart's contracting mechanism, since they should then be more numerous in advanced disease. The cell nuclei abnormalities resembled changes noted during activation of protein synthetic machinery. Analysis of HLA subtypes showed that a type of cellular damage can be associated with an HLA subtype. This finding is consistent with the hypothesis that DC is one of several diseases caused by the chemical product of an interaction between a virus and the immune system. The hypothesis holds that this product then becomes toxic to the body's cells. While implications of these results for treatment or progression of DC are not clear, clarification of the role of the immune system with respect to this disease could shed light on its etiology. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1989
31. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.
- Author
-
Pitcher, Alex, Emberson, Jonathan, Lacro, Ronald V, Sleeper, Lynn A, Stylianou, Mario, Mahony, Lynn, Pearson, Gail D, Groenink, Maarten, Mulder, Barbara J, Zwinderman, Aeilko H, De Backer, Julie, De Paepe, Anne M, Arbustini, Eloisa, Erdem, Guliz, Jin, Xu Yu, Flather, Marcus D, Mullen, Michael J, Child, Anne H, Forteza, Alberto, and Evangelista, Arturo
- Abstract
Rationale: A number of randomized trials are underway, which will address the effects of angiotensin receptor blockers (ARBs) on aortic root enlargement and a range of other end points in patients with Marfan syndrome. If individual participant data from these trials were to be combined, a meta-analysis of the resulting data, totaling approximately 2,300 patients, would allow estimation across a number of trials of the treatment effects both of ARB therapy and of β-blockade. Such an analysis would also allow estimation of treatment effects in particular subgroups of patients on a range of end points of interest and would allow a more powerful estimate of the effects of these treatments on a composite end point of several clinical outcomes than would be available from any individual trial.Design: A prospective, collaborative meta-analysis based on individual patient data from all randomized trials in Marfan syndrome of (i) ARBs versus placebo (or open-label control) and (ii) ARBs versus β-blockers will be performed. A prospective study design, in which the principal hypotheses, trial eligibility criteria, analyses, and methods are specified in advance of the unblinding of the component trials, will help to limit bias owing to data-dependent emphasis on the results of particular trials. The use of individual patient data will allow for analysis of the effects of ARBs in particular patient subgroups and for time-to-event analysis for clinical outcomes. The meta-analysis protocol summarized in this report was written on behalf of the Marfan Treatment Trialists' Collaboration and finalized in late 2012, without foreknowledge of the results of any component trial, and will be made available online (http://www.ctsu.ox.ac.uk/research/meta-trials). [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
32. Left Ventricular Noncompaction: A Distinct Cardiomyopathy or a Trait Shared by Different Cardiac Diseases?
- Author
-
Arbustini, Eloisa, Weidemann, Frank, and Hall, Jennifer L.
- Subjects
- *
CARDIOMYOPATHIES , *HEART diseases , *LEFT heart ventricle , *BIOMARKERS , *EPIDEMIOLOGY , *IMAGE analysis - Abstract
Whether left ventricular noncompaction (LVNC) is a distinct cardiomyopathy or a morphologic trait shared by different cardiomyopathies remains controversial. Current guidelines from professional organizations recommend different strategies for diagnosing and treating patients with LVNC. This state-of-the-art review discusses new insights into the basic mechanisms leading to LVNC, its clinical manifestations, treatment modalities, anatomy and pathology, embryology, genetics, epidemiology, and imaging. Three markers currently define LVNC: prominent left ventricular trabeculae, deep intertrabecular recesses, and a thin compacted layer. Although new genetic data from mice and humans supports LVNC as a distinct cardiomyopathy, evidence for LVNC as a shared morphological trait is not ruled out. Criteria supporting LVNC as a shared morphological trait may depend on consensus guidelines from the multiple professional organizations. Enhanced imaging and increased use of genetics are both predicted to significantly impact our overall understanding of the basic mechanisms causing LVNC and its optimal management. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
33. The MOGE(S) Classification of Cardiomyopathy for Clinicians.
- Author
-
Arbustini, Eloisa, Narula, Navneet, Tavazzi, Luigi, Serio, Alessandra, Grasso, Maurizia, Favalli, Valentina, Bellazzi, Riccardo, Tajik, Jamil A., Bonow, Robert D., Fuster, Valentin, and Narula, Jagat
- Subjects
- *
CARDIOMYOPATHIES , *FAMILIAL diseases , *MEDICAL screening , *CARDIOLOGISTS , *NOSOLOGY , *PHENOTYPES - Abstract
Most cardiomyopathies are familial diseases. Cascade family screening identifies asymptomatic patients and family members with early traits of disease. The inheritance is autosomal dominant in a majority of cases, and recessive, X-linked, or matrilinear in the remaining. For the last 50 years, cardiomyopathy classifications have been based on the morphofunctional phenotypes, allowing cardiologists to conveniently group them in broad descriptive categories. However, the phenotype may not always conform to the genetic characteristics, may not allow risk stratification, and may not provide pre-clinical diagnoses in the family members. Because genetic testing is now increasingly becoming a part of clinical work-up, and based on the genetic heterogeneity, numerous new names are being coined for the description of cardiomyopathies associated with mutations in different genes; a comprehensive nosology is needed that could inform the clinical phenotype and involvement of organs other than the heart, as well as the genotype and the mode of inheritance. The recently proposed MOGE(S) nosology system embodies all of these characteristics, and describes the morphofunctional phenotype (M), organ(s) involvement (O), genetic inheritance pattern (G), etiological annotation (E) including genetic defect or underlying disease/substrate, and the functional status (S) of the disease using both the American College of Cardiology/American Heart Association stage and New York Heart Association functional class. The proposed nomenclature is supported by a web-assisted application and assists in the description of cardiomyopathy in symptomatic or asymptomatic patients and family members in the context of genetic testing. It is expected that such a nomenclature would help group cardiomyopathies on their etiological basis, describe complex genetics, and create collaborative registries. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
34. Early Identification of Transthyretin-Related Hereditary Cardiac Amyloidosis ∗.
- Author
-
Arbustini, Eloisa and Merlini, Giampaolo
- Published
- 2014
- Full Text
- View/download PDF
35. Endomyocardial biopsy finding in two patients with idiopathic dilated cardiomyopathy receiving long-term treatment with amiodarone
- Author
-
Arbustini, Eloisa, Grasso, Maurizia, Salerno, Jorge A, Gavazzi, Antonello, Pucci, Angela, Bramerio, Manuela, Calligaro, Alberto, and Ferrans, Victor J.
- Subjects
Heart -- Biopsy, Needle ,Heart muscle -- Physiological aspects ,Amiodarone -- Adverse and side effects ,Anti-arrhythmia drugs -- Adverse and side effects ,Cardiomyopathy -- Drug therapy ,Health - Abstract
In normal circumstances, the heart muscle contracts in a synchronized, rhythmic fashion while it pumps blood to the body. In some disease conditions, the heartbeat can become irregular (arrhythmic) or the muscular contractions can become desynchronized (fibrillation), leading to a loss of the heart's ability to pump blood effectively. These disorders of rhythmicity are frequently treated with antiarrhythmic medications; amiodarone is a particularly effective example of this class of drug, and is frequently prescribed. However, it is not without side effects, and its accumulation in different tissues has been reported to cause a variety of adverse reactions. In previous studies, chronic amiodarone administration has been reported to cause the appearance of characteristic subcellular organelles in the liver, lymph nodes, blood cells, skin cells, intestinal mucosa, and nervous tissue. Animal studies have shown that amiodarone treatment can result in the appearance of these bodies in cardiac muscle cells, but this has not been reported in human studies. Two cases are described of patients with dilated cardiomyopathy (a condition in which the heart is enlarged) of unknown cause; a 50-year-old man and a 53-year-old woman had been receiving amiodarone to control cardiac arrhythmias for four and two years, respectively. Biopsy specimens taken from the right ventricle were viewed at high magnification using electron microscopy (enlarged 23,000 times). Numerous subcellular organelles seen within the cardiac myocytes (muscle fibers) of these patients appeared to be identical to those reported in other body tissues by investigators studying the effects of long-term amiodarone use. This finding is not common; of over 300 patients with dilated cardiomyopathy who underwent biopsy, 40 percent were receiving chronic amiodarone treatment, and of the 247 biopsy specimens analyzed, only these 2 showed this alteration. The implications of this morphological alteration are not known. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1991
36. Extra-Aortic Identifiers to Guide Genetic Testing in Familial Thoracic Aortic Aneurysms and Dissections Syndromes: It Is All About the Company One Keeps ⁎ [⁎] Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
- Author
-
Arbustini, Eloisa and Narula, Nupoor
- Published
- 2012
- Full Text
- View/download PDF
37. Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers: A European Cohort Study
- Author
-
van Rijsingen, Ingrid A.W., Arbustini, Eloisa, Elliott, Perry M., Mogensen, Jens, Hermans-van Ast, Johanna F., van der Kooi, Anneke J., van Tintelen, J. Peter, van den Berg, Maarten P., Pilotto, Andrea, Pasotti, Michele, Jenkins, Sharon, Rowland, Camilla, Aslam, Uzma, Wilde, Arthur A.M., Perrot, Andreas, Pankuweit, Sabine, Zwinderman, Aeilko H., Charron, Philippe, and Pinto, Yigal M.
- Subjects
- *
ARRHYTHMIA , *GENETIC mutation , *GENETIC carriers , *EUROPEANS , *VENTRICULAR tachycardia , *CONFIDENCE intervals , *CARDIOPULMONARY resuscitation , *DISEASE risk factors - Abstract
Objectives: The purpose of this study was to determine risk factors that predict malignant ventricular arrhythmias (MVA) in Lamin A/C (LMNA) mutation carriers. Background: LMNA mutations cause a variety of clinical phenotypes, including dilated cardiomyopathy and conduction disease. Many LMNA mutation carriers have a poor prognosis, because of a high frequency of MVA and progression to end-stage heart failure. However, it is unclear how to identify mutation carriers that are at risk for MVA. Methods: In this multicenter cohort of 269 LMNA mutation carriers, we evaluated risk factors for MVA, defined as sudden cardiac death, resuscitation, and appropriate implantable cardioverter-defibrillator (ICD) treatment. Results: In a median follow-up period of 43 months (interquartile range: 17 to 101 months), 48 (18%) persons experienced a first episode of MVA: 11 persons received successful cardiopulmonary resuscitation, 25 received appropriate ICD treatment, and 12 persons died suddenly. Independent risk factors for MVA were nonsustained ventricular tachycardia, left ventricular ejection fraction <45% at the first clinical contact, male sex, and non-missense mutations (ins-del/truncating or mutations affecting splicing). MVA occurred only in persons with at least 2 of these risk factors. There was a cumulative risk for MVA per additional risk factor. Conclusions: Carriers of LMNA mutations with a high risk of MVA can be identified using these risk factors. This facilitates selection of LMNA mutation carriers who are most likely to benefit from an ICD. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
38. High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study
- Author
-
Ferrario, Maurizio, Arbustini, Eloisa, Massa, Margherita, Rosti, Vittorio, Marziliano, Nicola, Raineri, Claudia, Campanelli, Rita, Bertoletti, Alessandra, De Ferrari, Gaetano Maria, Klersy, Catherine, Angoli, Luigi, Bramucci, Ezio, Marinoni, Barbara, Ferlini, Marco, Moretti, Enza, Raisaro, Arturo, Repetto, Alessandra, Schwartz, Peter J., and Tavazzi, Luigi
- Subjects
- *
ERYTHROPOIETIN , *MYOCARDIAL infarction treatment , *RANDOMIZED controlled trials , *PLACEBOS , *TREATMENT effectiveness , *MYOCARDIAL reperfusion , *CARDIAC magnetic resonance imaging , *ANGIOPLASTY - Abstract
Abstract: Background: Mortality and morbidity after acute myocardial infarction (AMI) remain high even when myocardial reperfusion is successful. Erythropoietin (EPO) protects against experimental MI. Methods: The aim of this single-centre study was to investigate the effects of short-term high-dose erythropoietin on peripheral blood cells (PBCs) and infarct size in 30 patients with a first uncomplicated AMI undergoing percutaneous coronary intervention (PCI) who were randomly assigned to treatment with EPO (33×103 IU before PCI, and 24 and 48h after admission), or placebo. We considered short-term CD34+ cell mobilisation, quantitative PBC gene expression in the apoptotic, angiogenic and inflammatory pathways, and enzymatically estimated infarct size. Echocardiographic and cardiac magnetic resonance studies were performed in the acute phase and six months later. Results: CD34+ cell mobilisation 72h after admission was greater in the EPO-treated patient group (93cells/μl [36–217] vs 22cells/μl [6–51]; p =0.002), who also showed higher expression of the anti-apoptotic AKT and NFkB, the pro-angiogenic VEGFR-2, and the EPO-R genes, and lower expression of the pro-apoptotic CASP3 and TP53 and pro-inflammatory IL12a genes. Moreover, they showed smaller infarct size (30% reduction in CK-MB release; p =0.025), and a favourable pattern of left ventricular remodelling. Conclusions: Short-term high-dose EPO administration in patients with AMI treated by PCI and standard anti-platelet therapy increases the levels of circulating CD34+ cells, shifts PBC gene expression towards anti-apoptotic, pro-angiogenic and anti-inflammatory pathways, and decreases infarct size. The clinical relevance of these results needs to be confirmed in specifically tailored trials. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
39. Human “Nuclear” Mitochondrial Cardiomyopathy: A Novel Mouse Model Characterizes the Disease ⁎ [⁎] Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily ...
- Author
-
Arbustini, Eloisa and Grasso, Maurizia
- Published
- 2011
- Full Text
- View/download PDF
40. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease
- Author
-
Arbustini, Eloisa, Pilotto, Andrea, Repetto, Alessandra, Grasso, Maurizia, Negri, Andrea, Diegoli, Marta, Campana, Carlo, Scelsi, Laura, Baldini, Elisa, Gavazzi, Antonello, and Tavazzi, Luigi
- Subjects
- *
CARDIOMYOPATHIES , *HIGH performance liquid chromatography - Abstract
: ObjectivesWe investigated the prevalence of lamin A/C (LMNA) gene defects in familial and sporadic dilated cardiomyopathies (DCM) associated with atrioventricular block (AVB) or increased serum creatine-phosphokinase (sCPK), and the corresponding changes in myocardial and protein expression.: BackgroundIt has been reported that familial DCM, associated with conduction disturbances or variable myopathies, is causally linked to LMNA gene defects.: MethodsThe LMNA gene and myocardial ultrastructural and immunochemical changes were analyzed in 73 cases of DCM (49 pure, 15 with AVB [seven familial, eight sporadic], 9 with increased sCPK), four cases of familial AVB and 19 non-DCM heart diseases. The normal controls included eight heart donor biopsies for tissue studies and 107 subjects for LMNA gene studies.: ResultsFive novel LMNA mutations (K97E, E111X, R190W, E317K, four base pair insertion at 1,713 cDNA) were identified in five cases of familial autosomal dominant DCM with AVB (5/15: 33%). The LMNA expression of the myocyte nuclei was reduced or absent. Western blot protein analyses of three hearts with different mutations showed an additional 30-kDa band, suggesting a degrading effect of mutated on wild-type protein. Focal disruptions, bleb formation and nuclear pore clustering were documented by electron microscopy of the myocyte nuclear membranes. None of these changes and no mutations were found in the nine patients with DCM and increased sCPK or in the disease and normal controls.: ConclusionsThe LMNA gene mutations account for 33% of the DCMs with AVB, all familial autosomal dominant. Increased sCPK in patients with DCM without AVB is not a useful predictor of LMNA mutation. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
41. Utilizing the MOGE(S) Classification for Predicting Prognosis in Dilated Cardiomyopathy.
- Author
-
Dec, G. William and Arbustini, Eloisa
- Subjects
- *
DILATED cardiomyopathy , *MEDICAL research , *HEALTH outcome assessment , *PROGNOSIS , *PATIENTS , *THERAPEUTICS , *PHENOTYPES - Published
- 2015
- Full Text
- View/download PDF
42. Clinical Imaging of ACS With Ruptured or Intact Fibrous Caps.
- Author
-
Arbustini, Eloisa, Narula, Nupoor, and Kodama, Takahide
- Published
- 2015
- Full Text
- View/download PDF
43. Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor.
- Author
-
Rampino, Teresa, Arbustini, Eloisa, Gregorini, Marilena, Guallini, Paola, Libetta, Carmelo, Maggio, Milena, Ranghino, Andrea, Silini, Enrico, Soccio, Grazia, and Dal Canton, Antonio
- Subjects
- *
LIVER diseases , *HEPATITIS C virus , *HEMODIALYSIS patients , *DISEASES - Abstract
Hemodialysis prevents liver disease caused by hepatitis C virus: Role of hepatocyte growth factor. Background. Hemodialysis increases markedly the serum levels of hepatocyte growth factor (HGF) so that regular dialysis treatment (RDT) mimics the regular administration of HGF as a drug. Therefore, we have studied the effects of dialysis-associated HGF production on the severity of liver damage caused by hepatitis C virus (HCV). Methods. Biochemical tests of liver function and liver biopsy were performed in 10 patients on RDT and in 11 patients without renal disease (WRD) converted to anti-HCV serum-positive test for the same time (48 ± 4 months). The HGF serum concentration was measured by enzyme immunoassay. In patients on RDT, HGF was measured just before starting a dialysis session (T0), at 15 and 240 minutes of dialysis (T15 and T240), and 24 hours later (T24 hr). Results. Serum HGF was similar in WRD (average 0.17 ng/ml) as in RDT at T0 (0.25 ng/ml). In RDT serum HGF increased markedly at T15 and T240 (5.51 and 2.67 ng/ml, respectively, P < 0.001 vs. WRD and T0) and was still higher than baseline at T24 hr (0.41 ng/ml, P < 0.05). Both grade of necroinflammatory activity and stage of fibrosis were significantly lower in RDT than in WRD (both, P < 0.001). The number of apoptotic hepatocytes was also significantly reduced in patients on RDT compared with patients WRD. Conclusion. These results show that HCV-related liver disease is more benign in patients on RDT. The phenomenon may depend on the marked and prolonged HGF release caused by dialysis. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
44. Enteroviral RNA and virus-like particles in the skeletal muscle of patients with idiopathic...
- Author
-
Arbustini, Eloisa and Grasso, Maurizia
- Subjects
- *
CARDIOMYOPATHIES , *PATHOLOGICAL physiology - Abstract
Investigates the role of chronic viral infection in the etiopathogenesis of idiopathic dilated cardiomyopathy. Ultrastructural study of heart samples and of skeletal muscle samples; Detection of the presence of enteroviral messenger ribonucleic acid; Ultrastructural changes in heart and skeletal muscle.
- Published
- 1997
- Full Text
- View/download PDF
45. Morphologic observations in the epicardial coronary arteries and their surroundings late after...
- Author
-
Arbustini, Eloisa and Roberts, William Cliffor
- Subjects
- *
CORONARY arteries , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Presents morphologic observations of the epicardial coronary arteries and their surroundings after cardiac transplantation. Types of intimal lesions; Differentiation of luminal shapes in post-transplant coronary arteries; Difference between pretransplant and post-transplant coronary lesions; Difference between intraluminal and intralesion thrombus.
- Published
- 1996
- Full Text
- View/download PDF
46. Frequency and characteristics of coronary thrombosis in the epicardial coronary arteries after...
- Author
-
Arbustini, Eloisa and Bello, Barbara Dal
- Subjects
- *
CORONARY disease , *CORONARY arteries , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Investigates the frequency and characteristics of coronary thrombosis in the epicardial coronary arteries after cardiac transplantation. Observation through autopsy and retransplantation; Utilization of hematoxylin-eosin and Movat pentachrome stains; Presence of thrombus.
- Published
- 1996
- Full Text
- View/download PDF
47. Reply: The MOGE(S) Classification for a Phenotype-Genotype Nomenclature of Cardiomyopathy: More Questions Than Answers?
- Author
-
Arbustini, Eloisa, Narula, Navneet, Dec, G. William, Reddy, K. Srinath, Greenberg, Barry, Kushwaha, Sudhir, Marwick, Thomas, Pinney, Sean, Bellazzi, Riccardo, Favalli, Valentina, Kramer, Christopher, Roberts, Robert, Zoghbi, William A., Bonow, Robert, Tavazzi, Luigi, Fuster, Valentin, and Narula, Jagat
- Published
- 2014
- Full Text
- View/download PDF
48. OCT/atherectomy/pathology studies open new perspectives for in vivo characterization of plaque composition.
- Author
-
Arbustini, Eloisa, Urtis, Mario, and Prati, Francesco
- Subjects
- *
ATHEROSCLEROTIC plaque , *PATHOLOGY , *OPTICAL coherence tomography - Published
- 2019
- Full Text
- View/download PDF
49. Assessment of Mechanisms of Acute Coronary Syndromes and Composition of Culprit Plaques in Patients With and Without Diabetes.
- Author
-
Ruscica, Giovanni, Gatto, Laura, Romagnoli, Enrico, Di Vito, Luca, Fabbiocchi, Franco, Marco, Valeria, Versaci, Francesco, Di Giorgio, Alessandro, Taglieri, Nevio, La Manna, Alessio, Fineschi, Massimo, Boi, Alberto, Niccoli, Gianpaolo, Albertucci, Mario, Crea, Filippo, Arbustini, Eloisa, Alfonso, Fernando, and Prati, Francesco
- Published
- 2019
- Full Text
- View/download PDF
50. Cyclosporin A in Reperfusion Injury: Not Opening to Cell Death Knocking at the Door?
- Author
-
Arbustini, Eloisa and Narula, Jagat
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.